Trial Profile
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications CNS cancer; Glioma
- Focus Adverse reactions; Pharmacokinetics
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00994071).
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00994071).
- 11 Jan 2013 Planned number of patients changed from 42 to 24 as reported by ClinicalTrials.gov.(NCT00946335).